Click Here for 5% Off Your First Aladdin Purchase!

Derazantinib(ARQ-087) - 99%, high purity , Fibroblast growth factor receptor inhibitor, CAS No.1234356-69-4, Fibroblast growth factor receptor inhibitor

  • Moligand™
  • ≥99%
Item Number
D302670
Grouped product items
SKUSizeAvailabilityPrice Qty
D302670-1mg
1mg
In stock
$45.90
D302670-5mg
5mg
In stock
$187.90
D302670-25mg
25mg
In stock
$642.90

Basic Description

SynonymsDerazantinib|1234356-69-4|ARQ-087|ARQ087|Derazantinib [USAN]|ARQ 087|Derazantinib (ARQ 087)|N9B0H171MJ|(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine|Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-
Specifications & Purity99%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionFibroblast growth factor receptor inhibitor
Product Description

Derazantinib(ARQ-087) is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3, showing lower potency for FGFR4 (IC50=34 nM). It also inhibits RET, DDR2, PDGFRβ, VEGFR and KIT.

Product Properties

ALogP5.3

Associated Targets

FGFR1 Tclin Fibroblast growth factor receptor 1 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR2 Tclin Fibroblast growth factor receptor 2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR3 Tclin Fibroblast growth factor receptor 3 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
INCHI InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
InChi Key KPJDVVCDVBFRMU-AREMUKBSSA-N
Canonical SMILES COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
Isomeric SMILES COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
PubChem CID 46834118
Molecular Weight 468.57

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
I2126029Certificate of AnalysisJul 16, 2024 D302670
I2126030Certificate of AnalysisJul 16, 2024 D302670
I2126397Certificate of AnalysisJul 16, 2024 D302670

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H335:May cause respiratory irritation

H302:Harmful if swallowed

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

Related Documents

References

1. Hall TG, Yu Y, Eathiraj S, Wang Y, Savage RE, Lapierre JM, Schwartz B, Abbadessa G.  (2016)  Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation..  PLoS ONE,  11  (9): (e0162594).  [PMID:27627808]
2. Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE et al..  (2017)  A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours..  Br J Cancer,  117  (11): (1592-1599).  [PMID:28972963]

Solution Calculators